Abstract: The present invention provides a formulation of a Factor VIII polypeptide, e.g., FVIII-Fc, and methods of using the same. The FVIII polypeptide can be a recombinant FVIII protein, a short-acting FVIII protein, or a long-acting FVIII protein. The pharmaceutical formulation comprising a FVIII polypeptide can be used for individual prophylaxis, weekly prophylaxis, episodic (on-demand) treatment, or perioperative management of hemophilia.

Abstract: The present disclosure relates to pharmaceutical compositions comprising a non-naturally occurring fusion molecule and one or more pharmaceutically acceptable carriers, formulated for oral delivery to a subject, and designed to provide for improved, effective therapies for treatment of, e.g., inflammatory diseases, autoimmune diseases, cancer, metabolic disorders, and growth deficiency disorders.

Abstract: The present disclosure relates to pharmaceutical compositions comprising a non-naturally occurring fusion molecule and one or more pharmaceutically acceptable carriers, formulated for oral delivery to a subject, and designed to provide for improved, effective therapies for treatment of, e.g., inflammatory diseases, autoimmune diseases, cancer, metabolic disorders, and growth deficiency disorders.

Abstract: Compositions and methods useful for the treatment of neuromyelitis optica (NMO) or neuromyelitis optica spectrum disorder (NMOSD) are disclosed.

Abstract: A method for forming microspheres containing bioactive material, comprising dissolving a polymer matrix, such as albumin or beta-cyclodextrin, in an aqueous medium in a first vessel; contacting the dissolved polymer matrix with a crosslinking agent, such as glutaraldehyde, to crosslink the polymer matrix and the crosslinking agent; neutralizing with sodium bisulfate any excess crosslinking agent remaining after crosslinking is substantially complete; solubilizing in a second vessel a bioactive material in an aqueous solution; mixing the solubilized bioactive material together with the neutralized crosslinked polymer matrix in solution to form a mixture; and, spray drying the mixture to produce nanospheres, whereby substantial bioactivity of the biomaterial is retained upon cellular uptake.

Abstract: Methods of preparing mutants of Mycobacterium tuberculosis with one or more disrupted genes are presented, where the disrupted genes include ctpV, rv0990c, rv0971c, and/or rv0348. Compositions containing mutants with attenuated virulence and pathogenesis, which are capable of stimulation of an immune response against tuberculosis, are described. Compositions and methods relating to immunogenic compositions, which include an attenuated M. tb strain in which the M. tb genome includes a disruption of at least one of the ctpV gene, the rv0990c gene, the rv0971c gene, and the rv0348 gene, are also provided.

Abstract: The present disclosure is based upon the identification of a number of Streptococcus agalactiae genes which are required for virulence in fish species. Specifically, the disclosure relates to genomic content present in fish-associated S. agalactiae strains that is absent from strains which are non-virulent to fish. Further disclosed is the use of a number of S. agalactiae proteins and antigens in methods, immunogenic compositions and vaccines for raising immune responses and treating or preventing diseases, conditions and/or infections with a Streptococcal aetiology.

Abstract: An object of the present invention is to provide immunogenic compositions for protection against S. pneumoniae, in particular against S. pneumoniae serogroup 10A and 39, while limiting the number of conjugates. The present invention therefore relates to new immunogenic compositions for use in pneumococcal vaccines and to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said immunogenic compositions.

Abstract: The present disclosure relates to surface proteins of Moraxella catarrhalis and their ability to interact with epithelial cells via cell-associated fibronectin and laminin, and also to their ability to inhibit the complement system. These surface proteins are useful in the preparation of vaccines. The present disclosure also provides peptides interacting with fibronectin, laminin and the complement system.

Abstract: A thermostable formula comprises the following components in percentage by mass: 1% to 5% raffinose, 5% to 10% maltose, 15% to 30% saccharose, 1% to 5% lactose, 1% to 5% glucose, 0.1% to 1.5% polysorbate 80, 0.1% to 0.5% polyethylene glycol 8000, 0.5% to 3% tyrosine, 3% to 6% silk fibroin, and the balance of water for injection. It further discloses a room-temperature-preserved live classical swine fever vaccine and a preparation method thereof, wherein the live classical swine fever vaccine is obtained by mixing the thermostable formula with a live classical swine fever virus solution and then carrying out gradient vacuum drying. The vaccine prepared according to the present invention has a dried foam appearance and presents a glass-layer like structure under a scanning electron microscope, has a glass transition temperature up to more than 50° C.

Abstract: Disclosed is an adapted Madin-Darby canine kidney cell line capable of suspension culture in the absence of serum, and a chemically-defined medium for culture of the adapted MDCK cell line. Further disclosed are culture methods for growing the adapted MDCK cell line and methods for producing a vaccine from the adapted MDCK cell line grown in the chemically-defined medium.

Abstract: Provided herein are compositions including a probiotic including at least one strain of live bacteria and a Marek's Disease vaccine. Compositions including a probiotic or a probiotic and a Marek's Disease vaccine may be administered to subjects, including poultry. The compositions may be administered in ovo to increase early lactic acid bacteria in the gastrointestinal tract of the subject, to decrease the gram negative bacteria in the gastrointestinal tract of the subject, to reduce the level of Salmonella in the gastrointestinal tract of the subject and to increase the body weight gain of the subject. Also provided are kits including a probiotic and a Marek's Disease vaccine.

Abstract: The invention provides aqueous pharmaceutical adalimumab compositions suitable for long-term storage of adalimumab, methods of manufacture of these compositions, methods of administration, and kits containing same.

Abstract: A stable anti-PD-1 antibody pharmaceutical preparation and an application thereof in a medicine. The anti-PD-1 antibody pharmaceutical preparation comprises an anti-PD-1 antibody, a buffer, and can further comprise at least one type of stabilizer, and optionally can further comprise a surfactant. The anti-PD-1 antibody pharmaceutical preparation of the present invention can effectively suppress antibody aggregation and deamidation, thereby preventing degradation of an antibody product, resulting in a stable injectable pharmaceutical preparation.

Abstract: A non-replicating recombinant adeno-associated associated virus (rAAV) having an AAV capsid having packaged therein a vector genome which comprises AAV inverted terminal repeat sequences and at least one nucleic acid sequence encoding four different immunoglobulin regions (a), (b), (c) and (d) is provided. The rAAV-expressed immunoglobulins are useful for providing passive immunization against influenza A and influenza B. Also described herein are compositions containing the rAAV. Methods of vaccinating patients against influenza are provided.

Abstract: A group of Hyperthermia micro/nano particles are prepared. Each nanoparticle has a first diameter between 1 micron to 50 micron and a first thickness between 100 nm to 5 micron, in a disk-like shape. The hyperthermia micro/nano particles in the present show enhanced heat properties under microwave radiation which can be used for diagnosis and therapeutic purpose in cancer treatment.

Abstract: The present invention provides methods and compositions for the remote control of cell function based on the use of radiofrequency waves to excite nanoparticles targeted to specific cell types. The nanoparticles may be applied to the target cell extracellularly and/or expressed intracellularly. The cell type of interest expresses a temperature sensitive channel wherein excitation of the nanoparticles results in a localized temperature increase that is transduced into a cellular response. Such cellular responses may include, for example, increases in gene expression resulting in production of one or more physiologically active proteins. The expression of such proteins can be used to treat a variety of different inherited or acquired diseases or disorders in a subject. Accordingly, the invention provides a generic approach for treatment of any disease associated with a protein deficiency.

Abstract: The present invention relates to a pharmaceutical topical gel solution that contains 5-aminolevulinic acid (5-ALA) and an aqueous low viscous gel matrix. This invention also relates to a pharmaceutical preparation containing this composition. The formulation of this type can be used in photodynamic therapy as well as in the photodynamic detection of abnormally proliferating cells.

Abstract: The present invention relates to an apparatus for inhibiting oncogene-induced malignant carcinogenesis, including an irradiation unit for applying low-dose radiation to a subject, and to a method of inhibiting oncogene-induced malignant carcinogenesis, including applying low-dose radiation to a subject, whereby oncogene-induced malignant carcinogenesis can be inhibited by means of the apparatus and method of the present invention.

Abstract: A composition includes a composite material including at least one conducting polymer doped with graphene oxide and at least one agent immobilized at least one of (i) on graphene oxide extending from the surface of the composite material or (ii) within the composite material.

Abstract: The present disclosure is directed to transdermal and moisturizing compositions.

Abstract: A self-emulsifying composition contains: 70 to 90% by weight of at least one compound selected from the group consisting of ?3 polyunsaturated fatty acids and their pharmaceutically acceptable salts and esters; 0.5 to 6% by weight of water; 1 to 29% by weight of a polyoxyethylene sorbitan fatty acid ester as an emulsifier (optionally including a polyoxyl castor oil, and not including lecithin); and lecithin in an amount of 3 to 40 parts by weight in relation to 100 parts by weight of ?3 polyunsaturated fatty acids and the like. The self-emulsifying composition is excellent in self-emulsifying property, composition dispersibility, emulsion stability, and absorbability, is free from ethanol and polyhydric alcohols or only has such an alcohol added thereto at a reduced concentration, and is useful for foods and pharmaceuticals.

Abstract: The invention provides a conjugate comprising a biomolecule linked to a fatty acid via a linker wherein the fatty acid has the following Formulae A1, A2 or A3: wherein R1, R2, R3, R4, Ak, n, m and p are defined herein. The invention also relates to a method for manufacturing the conjugate of the invention such as GDF15 conjugate, and its therapeutic uses such as treatment or prevention of metabolic disorders or diseases, type 2 diabetes mellitus, obesity, pancreatitis, dyslipidemia, alcoholic and nonalcoholic fatty liver disease/steatohepatitis and other progressive liver diseases, insulin resistance, hyperinsulinemia, glucose intolerance, hyperglycemia, metabolic syndrome, hypertension, cardiovascular disease, atherosclerosis, peripheral arterial disease, stroke, heart failure, coronary heart disease, diabetic complications (including but not limited to chronic kidney disease), neuropathy, gastroparesis and other metabolic disorders.

Abstract: Pharmaceutical composition comprising glutathione disulphide or pharmaceutically acceptable organic or inorganic salt thereof and glutathione disulfide S-oxide of the following structure: or pharmaceutically acceptable organic or inorganic salt thereof for eliminating dose-related toxicity and enhancing the therapeutic activity of a pharmacologically active compound in the treatment of infectious and non-infectious diseases is provided. Typically, the composition comprises glutathione disulfide S-oxide in an amount of 0.01-10% by weight of the total composition, and additionally a metal (Me) in the form of coordination compound(s) containing Me-S-glutathione bond, said metal is selected from the platinum group, typically it is platinum. The amount of d-metal coordination compound administered to a patient can be 10?3 to 10?15 mol/kg of body weight.

Abstract: The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.

Abstract: Disclosed herein is the use of Mycobacterium tuberculosis antigens for use in in vivo determination of the presence of Mtb infection in immunocompromised persons or persons co-infected with HIV and the for preparing a diagnostic reagent for skin testing (a skin test reagent) for robust assessment of the presence of Mtb infection infection in an individual wherein the individual is an immunocompromised person or a person co-infected with HIV.

Abstract: Compounds are described herein where CCK2R targeting ligands are attached to an imaging agent through a linker. The compounds can be used in the detection, diagnosis, imaging and treatment of cancer.

Abstract: Implantable materials may be used in an iatrogenic site. Applications include radioopaque materials for fiducial marking.

Abstract: Provided herein are compositions Gd(III)-dithiolane gold nanoparticle conjugates and methods of use thereof. In particular, compositions and method find use in in vivo imaging (e.g., magnetic resonance imaging (MRI)), for example, of pancreatic tissue.

Abstract: The present invention relates to an aqueous formulation for use in diagnostic detection wherein the aqueous formulation is administered prior to the administration of a fluorinated contrast agent or composition comprising a fluorinated contrast agent as well as to a method of administration. The invention further relates to the use of said aqueous formulation for the diagnostic detection of inflammatory pathological conditions using MR imaging. In addition the invention relates to a kit as well as a diagnostic kit suitable for use in diagnostic detection.

Abstract: A retrofit device and method adapt an existing, conventional lighting fixture for resisting bio-fouling of a primary window of the lighting fixture when submerged and exposed to biological organisms within a surrounding environment. The primary window is isolated from the surrounding environment by an auxiliary window member, and ultraviolet radiation is directed to the outer surface of the auxiliary window member from a source within the retrofit device, enabling transmission of ultraviolet radiation to the outer surface of the auxiliary window member of an intensity limited to essentially that which is effective in rendering the outer surface of the auxiliary window member immune to permanent adherence of biological organisms to which that outer surface is exposed when submerged, thereby allowing illumination from a source behind the primary window to be projected effectively through the auxiliary window member into the surrounding environment.

Abstract: A light delivery system and method are provided to promote a photochemical reaction for disinfecting a surface. The system includes a light source and a light diffusing element operatively coupled to the light source and further embedded within a surface to be disinfected. The light diffusing element outputs light to the surface to promote a photochemical reaction to disinfect the surface. A low scatter light transmission medium may further be coupled between the light source and the light diffusing element to transmit light from the light source remotely to the light diffusing element.

Abstract: Disclosed are a microbe inactivation processing device that can perform inactivation processing of microbes, while damage to human body cells is prevented or inhibited, with an efficient use of light emitted from a light source and the obtainment of a large effective irradiation area. Also provided are a cell activation processing device that can reliably activate target cells with high efficiency. The microbe inactivation processing device includes: a light source configured to emit light having a wavelength within a wavelength range of 190 nm to 237 nm; a power supply unit configured to supply electric power to the light source; a control unit configured to control the power supply unit; and an optical filter. The microbe inactivation processing device is configured to perform inactivation processing of a target microbe by applying the light emitted from the light source through the optical filter.

Abstract: A method and apparatus for cleaning and treating HVAC systems with a deployed agent preferably includes an aerosol generating device, a plurality of vent sealing devices, an outlet connection conduit and an inlet connection conduit. The HVAC system includes at least one supply duct and at least one return duct. The aerosol generating device includes an inlet and an outlet. The outlet is connected to a return vent of the at least one return duct with the outlet connection conduit. A supply vent of the at least one supply duct may be connected to the inlet with the inlet connection conduit. However, the inlet does not have to be connected to the supply vent if the aerosol generating device is retained in an enclosure. A booster chamber may be used to increase the flow rate of the deployed agent from the aerosol generating device.

Abstract: Systems and methods for sterilizing an enclosed space using ozone are disclosed herein. Various embodiments of the devices and methods also provide for accelerated degradation of the ozone upon sterilization. The methods can include identifying enclosed spaces, sterilizing enclosed spaces through ozone generation, generating reports and transmitting the reports. The sterilization unit disclosed herein can sterilize a plurality of enclosed spaces, such as a fleet of medical response vehicles.

Abstract: A sterilization cabinet, comprising a top panel, at least two side panels, and a floor panel forming a part of a chamber of the sterilization cabinet; at least one door connected to at least one of the at least two side panels of the sterilization cabinet; a vent formed in at least one of the two side panels; at least one first filter covering the vent and a filter cover configured to hold the first filter against the vent; a drain positioned in the floor panel, wherein the floor panel has a slope configured to cause condensate within the chamber to flow into the drain and wherein the drain is the only outlet for the condensate along the floor panel; and a second filter covering the drain such that condensate flowing into the drain passes through the second filter.

Abstract: A volatile substance evaporator device comprising a heat source and a refill including said volatile substances, wherein the heat source is a flame that heats a transmission element which heats said refill for evaporating the volatile substances. The result thereof is that the volatile substances evaporate properly without the need to use batteries or a similar power source, simply by the use of a flame, for example in the form of a candle, the financial cost thereof being very low.

Abstract: A contaminant reducing device is provided. The contaminant reducing device comprises: an exhaust gas tube for supplying exhaust gas from a combustion engine; a cleaning water supply tube for supplying cleaning water; a scrubber for spraying cleaning water, which is supplied through the cleaning water supply tube, to exhaust gas supplied through the exhaust gas tube; an oxidation unit connected to the exhaust gas tube so as to oxidize the exhaust gas by discharging electricity, emitting ultraviolent rays, or spraying an oxidizer; and a cleaning water discharge tube for discharging cleaning water from inside the scrubber.

Abstract: A photocatalytic reactor housing having a longitudinal axis allowing a fluid to flow through; a frame holding a light source and blades substantially encompassing the light source around the longitudinal axis; each blade having an interior surface facing the light source and an exterior surface opposite the interior surface; at least a portion of the surface of a plurality of the blades having a coating of material with photocatalytic oxidative properties; and the interior surface of the blade configured to redirect some amount of the light emitted onto another portion of substrate of an adjacent blade. In one embodiment the blades are tilted in the radial direction along at least a portion of the blades. In one embodiment the interior surface is configured to reflect some of the light emitted by the light source on to at least a portion of the exterior surface of an adjacent blade.

Abstract: A flexible electrode assembly for an air treatment device comprising: a flexible dielectric layer forming an insulating sheet; a plurality of conductive tracks on a first side of the insulating sheet; a conductive layer on a second side of the insulating sheet; wherein supply of voltage to the conducting tracks and the conductive layer generates plasma which is discharged from the conducting tracks. In a further aspect, the present invention also provides an air treatment apparatus for removal of health threatening airborne pollutants, which may include pathogens, from an air flow, the air treatment apparatus comprising an apparatus having a generally cyclonic-shaped geometry comprising a cylindrical section and a conical section. The present invention also relates to an air treatment device comprising the flexible electrode assembly.

Abstract: The invention includes a hot melt adhesive composition based on polyolefin polymers that can be used for construction applications in a disposable absorbent article. The olefin based hot melt adhesive composition has surprisingly good cohesive strength and a low odor.

Abstract: According to an illustrative embodiment a method to promote healing of a wound is provided comprising contacting the wound with a biologically active composition comprising a lipoic acid derivative and gelatin. In another embodiment a topical composition is provided, which can be formulated as a homogenous mixture, such as a spray, mist, aerosol, lotion, cream, solution, oil, gel, ointment, paste, emulsion or suspension or applied on a carrier material, such as a bandage, gauze, foam, sponge, hydrogel, hydrocolloid, hydrofiber, occlusive dressing, adhesive composition or scaffold. Methods for producing such a topical composition and carrier material with the topical composition applied thereto are also disclosed.

Abstract: In various aspects, the present disclosure pertains to methods of treating or preventing bleeding at a tissue site comprising applying a chitosan powder composition to the tissue site. In various aspects, the present disclosure pertains to chitosan powder compositions for application to a tissue site, where the powder compositions comprise a chitosan salt, a crosslinked chitosan, a derivatized chitosan, or a combination thereof. In various aspects, the disclosure pertains to catheter assemblies, which are preloaded with a chitosan powder composition and which are configured to deliver the chitosan powder composition a tissue site.

Abstract: The present invention relates to methods for producing biphasic calcium phosphate materials using chemical processing methods including exposure to peroxides. The resulting materials exhibit an osteoinductive needle-like surface morphology and are useful as artificial bone grafts.

Abstract: The present invention relates to a collagen-silk fibroin co-assembled sponge material, co-assembled artificial skin and a preparation method thereof. The collagen-silk fibroin co-assembled sponge material has an ordered porous spatial structure and is prepared from a collagen-silk fibroin co-assembled product obtained by co-assembly of collagen and silk fibroin. The co-assembled artificial skin comprises a collagen-silk fibroin co-assembled sponge dermis and an epidermis. The dermis of the co-assembled artificial skin provided in the present invention is similar to the natural extracellular matrix in composition and structure. This kind of ordered novel structure can induce ordered arrangement and regeneration of cells, thereby promoting wound healing, reducing scar formation and achieving good biocompatibility.

Abstract: Provided are an implanted medical device (1) and preparation method thereof, and an implanted medical device preform for preparing the implanted medical device (1). The implanted medical device (1) comprises a metal basal body (21) and a polymer film layer (22) covering the surface of the metal basal body (21) and preventing endothelium growth and covering, wherein at least a part of the surface of the metal basal body (21) is provided with a surface-modified layer (211) which contains doped ions, and the metal basal body (21) is connected to the polymer film layer (22) by the doped ions. Since the metal basal body (21) may be bonded to the polymer film layer (22) by the doped ions, the polymer film layer (22) is unlikely to separate during delivery, therefore effectively preventing endothelium growth and covering in vivo.

Abstract: Methods of preparing a human birth tissue material are provided. A placental construct for treatment of a disease or condition is also provided. A kit including at least one placental construct and at least one structural carrier is provided. A catheter for recovering amniotic fluid is also provided.

Abstract: Compositions and methods for the surface appearance of the skin a subject are provided. An injectable composition comprising at least hyaluronic acid or a salt thereof; and an effective amount of at least mepivacaine or a salt thereof are provided. The hyaluronic acid optionally has an average molecular weight ranging from 50,000 to 10,000,000 Daltons, and may be crosslinked hyaluronic acids, non-crosslinked hyaluronic acids, or a combination, in some embodiments. The compositions and methods of the present invention are useful for treating and preventing the cutaneous signs of chronological aging and/or induced by external factors such as stress, air pollution, tobacco or prolonged exposure to ultraviolet (UV) exposure, impaired surface appearance of the skin, impaired viscoelastic or biomechanical properties of the skin, and/or the long-lasting filling of volume defects of the skin.

Abstract: Disclosed is a method for treating a surface of an implant. The disclosed method for treating the surface of the implant comprises the steps of: coating a surface treatment composition containing an organic material having a hydrophilic group on the surface of the implant (coating step); and drying the coated surface treatment composition (drying step).

Abstract: A multilayer sheet can be used in vivo or in an environment in which moisture is adhered, an integrated sheet including the multilayer sheet and a base material, and methods for producing the same. The multilayer sheet has one or more layers from each of a layer (A) composed of sparingly water-soluble polymer and a fiber layer (B) composed of water-soluble polymer are laminated, and at least one of outermost layers is the above-described layer (A) composed of sparingly water-soluble polymer. The time taken from dropping of water onto a surface of the outermost layer of the above-described layer (A) composed of sparingly water-soluble polymer to dissolution of the other outermost layer is 10 seconds to 5 minutes.